Cell

Bestqool Unveils the Key to Optimal Health: The Perfect Duration for Red Light Therapy Sessions

Retrieved on: 
Tuesday, March 26, 2024
Pigment, Health, Radiation, Burns, Fibromyalgia, Cell, Inflammation, Patient, Tissue, Muscle fatigue, Athlete, Arthritis, Light, Wound healing, Skin, Safety, Red light, Low-level laser therapy, Ageing, Medical imaging

Seattle, Washington, March 26, 2024 (GLOBE NEWSWIRE) -- In an exciting development for wellness enthusiasts and health-conscious individuals, Bestqool, has announced its insights into the optimal duration for Red Light Therapy sessions.

Key Points: 
  • Seattle, Washington, March 26, 2024 (GLOBE NEWSWIRE) -- In an exciting development for wellness enthusiasts and health-conscious individuals, Bestqool, has announced its insights into the optimal duration for Red Light Therapy sessions.
  • This revelation promises to enhance the efficacy and safety of Red Light Therapy, a popular and effective treatment that has captivated global attention for its numerous health benefits.
  • How Long Should Red Light Therapy Sessions Last?
  • In pain relief, Red Light therapy duration can last as long as 15 to 30 minutes instead.

Synthekine Presents Positive Initial Results from Phase 1a/1b Clinical Trial of α/β Biased IL-2, STK-012, for Treatment of Advanced Solid Tumors

Retrieved on: 
Tuesday, April 9, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Arthralgia, Toxicity, Cell, NSCLC, RECIST, HNSCC, Patient, Diarrhea, Maculopapular rash, Lung cancer, Renal cell carcinoma, Injection site reaction, AACR, Nausea, Lymphocyte, Hypotension, RCC, Transaminase, Poster, Itch, CLS, Capillary leak syndrome, Fatigue, Vomiting, NK, Inc., Pharmaceutical industry

Synthekine Inc ., an engineered cytokine therapeutics company, today announced positive initial results from a Phase 1a/1b clinical trial of its α/β biased IL-2 partial agonist, STK-012, for the treatment of advanced solid tumors.

Key Points: 
  • Synthekine Inc ., an engineered cytokine therapeutics company, today announced positive initial results from a Phase 1a/1b clinical trial of its α/β biased IL-2 partial agonist, STK-012, for the treatment of advanced solid tumors.
  • The data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego.
  • In the results presented, which included 47 patients treated in Phase 1a dose escalation, STK-012 monotherapy demonstrated a favorable safety, efficacy, pharmacokinetic and pharmacodynamic profile.
  • The poster, titled “Initial results from a Phase 1a/1b study of STK-012, a first-in-class α/β IL-2 receptor biased partial agonist in advanced solid tumors (NCT05098132),” will be presented today at AACR from 9 am to 12:30 pm PT.

Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024

Retrieved on: 
Tuesday, April 9, 2024
Research, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, B cell, Immunity, Cell, Patient, City, Tumor microenvironment, Cancer, AACR, Chemokine, Clinical trial, Immune system, Virus, Potyvirus, Poster, Vaccine

The poster, titled “Deciphering anticancer mechanisms of oncolytic virus-loaded stem cells,” will be presented on April 9, 2024, during the Chemotherapy, Radiation, and Vaccine Mediated Immunity session.

Key Points: 
  • The poster, titled “Deciphering anticancer mechanisms of oncolytic virus-loaded stem cells,” will be presented on April 9, 2024, during the Chemotherapy, Radiation, and Vaccine Mediated Immunity session.
  • “Calidi’s novel approach to treating cancer has always centered around the stem cell as a means of protecting, delivering, and potentiating our tumor-killing virotherapeutic payloads.
  • In the studies presented at AACR, scientists at Calidi Biotherapeutics and City of Hope researched the stem cells secretome transcriptomic of CLD-101 and CLD-201.
  • This poster will be posted to the “Scientific Publications” section of the Calidi Biotherapeutics website following the conclusion of the conference.

Nvelop Therapeutics Launches with Dual Platforms for In Vivo Delivery of the Next Generation of Genetic Medicines

Retrieved on: 
Tuesday, April 9, 2024
Research, Medical Supplies, Infectious Diseases, Genetics, Biotechnology, Other Health, Health, Pharmaceutical, Science, Culture, Broad Institute, Cell, Massachusetts General Hospital, Partner (business rank), Environment, Trust, RNP, MIT, Spark Therapeutics, Patient, Harvard University, Nature Biotechnology, Tissue, Head, Protein, Therapy, Former, Safety, Royal Naval Patrol Service, FDA, Management

Nvelop Therapeutics , a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of therapeutic cargo, today formally announced its launch to develop the next generation of genetic medicines for a wide range of diseases.

Key Points: 
  • Nvelop Therapeutics , a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of therapeutic cargo, today formally announced its launch to develop the next generation of genetic medicines for a wide range of diseases.
  • The company’s approach has the potential to enable highly efficient and cell-specific delivery of a broad set of therapeutic cargoes.
  • “The field of genetic medicine is significantly limited by the challenge of efficiently delivering therapeutic cargoes to many types of target cells in vivo,” said Jeff Walsh, Nvelop’s Chief Executive Officer.
  • In vivo data for the second platform is expected to be disclosed at one or more scientific meetings this year.

FORE Biotherapeutics to Present Nonclinical Data at the 2024 AACR Annual Meeting Supporting Superior Potency for Plixorafenib Compared with BRAF or Pan-Raf Inhibitors, When Combined with MEK Inhibition

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Safety, BRAF, Meki, Binimetinib, BRAF V600, Cell, MEK, Pharmaceutical industry

The data show nonclinical synergistic activity of plixorafenib when combined with MEK inhibition across all BRAF alterations tested.

Key Points: 
  • The data show nonclinical synergistic activity of plixorafenib when combined with MEK inhibition across all BRAF alterations tested.
  • In cells with BRAF V600 or non-V600 mutations or BRAF fusions, the combination of plixorafenib and binimetinib is most potent of the BRAF and pan-RAF inhibitors tested.
  • To date, plixorafenib has demonstrated encouraging efficacy and safety data from the phase 1/2a study; these nonclinical data help build the foundation for potential future development of plixorafenib in combination with a MEK inhibitor.
  • Poster Title: The paradox-breaker BRAF inhibitor plixorafenib (PLX8394; FORE8394) synergizes with MEK inhibitors (MEKi) in BRAF V600 and non-V600 alterations, with higher potency compared to early generation BRAFi and pan-RAFi

Tubulis Presents Preclinical Data for Solid Tumor Targeting ADC Candidates TUB-030 and TUB-040 Demonstrating Superior Efficacy Profile and a Wide Therapeutic Window at the AACR Annual Meeting 2024

Retrieved on: 
Monday, April 8, 2024
Oncology, Health, Clinical Trials, Research, Science, Biotechnology, Ovarian cancer, Translocase, 5T4, Cell, NSCLC, Adenocarcinoma, Patient, Neoplasm, Immunoglobulin G, Cancer, Cancer research, Spacecraft, Translation, Abstract, AACR, ADC, Non-small-cell lung cancer, Vaccine

Tubulis today presented comprehensive preclinical data on its two lead antibody-drug conjugate (ADC) candidates TUB-030 and TUB-040 at this year’s Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.

Key Points: 
  • Tubulis today presented comprehensive preclinical data on its two lead antibody-drug conjugate (ADC) candidates TUB-030 and TUB-040 at this year’s Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.
  • The poster presentations contained preclinical data, highlighting the ability of the two next-generation Tubutecan ADCs to create effective and durable responses even in low target-expressing tumor mouse models.
  • Tubulis is leveraging a proprietary suite of platform technologies to build a pipeline of uniquely matched ADC candidates that combine the right targeting molecule, conjugation chemistry and payload to deliver the true therapeutic value of the ADC approach.
  • The company’s lead candidates, both targeting solid tumor indications, are in late-stage preclinical testing, with TUB-040 ready for clinical evaluation.

Global and China Passenger Car Cell to Pack, Cell To Chassis and Cell to Body Integrated Battery Industry Report 2024: Currently Only Tesla, BYD, Leapmotor and Xpeng have Released CTC/CTB Technology - ResearchAndMarkets.com

Retrieved on: 
Monday, April 8, 2024
Vehicle Technology, EV, Electric Vehicles, Other Energy, Alternative Energy, Alternative Vehicles, Fuels, Batteries, General Automotive, Energy, Technology, Automotive, Automotive Manufacturing, Other Automotive, Manufacturing, Leapmotor, JAC, CIB, Volvo, CTB, BYD, Model Y, Cell, Original equipment manufacturer, Acceleration, EVS, Volkswagen, Nm, Gigafactory Texas, CTC, CATL, CTP, SAIC, Electric battery

The "Passenger Car CTP (Cell to Pack), CTC (Cell To Chassis) and CTB (Cell to Body) Integrated Battery Industry Report, 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Passenger Car CTP (Cell to Pack), CTC (Cell To Chassis) and CTB (Cell to Body) Integrated Battery Industry Report, 2024" report has been added to ResearchAndMarkets.com's offering.
  • Currently only four automakers Tesla, BYD, Leapmotor and Xpeng have released CTC/CTB technology and applied it in production models.
  • Leapmotor: In April 2022 Leapmotor released CTC technology, and first applied it to the production model Leapmotor C01.
  • In addition to Tesla, BYD, Leapmotor and Xpeng, Xiaomi, Volkswagen, Volvo, JAC and SAIC all make layout of CTC technology.

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024
Lung, TUSC2, Agonal respiration, Metabolism, Gene, Apoptosis, Cell, NSCLC, Nanoparticle, Patient, Neoplasm, Research, Pembrolizumab, Date, NPRL2, Lung cancer, Immunity, ATP, ALK, Glycolysis

AUSTIN, Texas, April 9, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data for Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid) and NPRL2 gene therapy, which both utilize the Company's non-viral Oncoprex® Delivery System for the treatment of lung cancer. These studies were presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting, which is being held April 5-10, 2024 in San Diego, California.

Key Points: 
  • Alectinib is an ALK-inhibitor commonly used to treat patients with ALK rearrangements such as EML4-ALK positive NSCLCs.
  • This research suggests that REQORSA may be an effective treatment in patients progressing on alectinib.
  • The study found that the NPRL2 treatment by itself led to a marked decrease in the size of lung metastases but pembrolizumab had no effect.
  • Study findings suggest that NPRL2 gene therapy induces anti-tumor activity against KRAS/STK11mt tumors through dendritic cell-mediated antigen presentation and cytotoxic immune cell activation.

Virtuosi® Becomes an IACET Accredited Provider

Retrieved on: 
Tuesday, April 9, 2024
Microbiology, Organization, Accreditation, VR, Education, Aseptic processing, Senior, Quality, Continuing education, Cell, ANSI, Virtual reality, Nursing

ATLANTA, April 9, 2024 /PRNewswire/ --The International Accreditors for Continuing Education and Training (IACET) has awarded Virtuosi the prestigious Accredited Provider accreditation. IACET Accredited Providers are the only organizations approved to offer IACET Continuing Education Units (CEUs).

Key Points: 
  • ATLANTA, April 9, 2024 /PRNewswire/ --The International Accreditors for Continuing Education and Training (IACET) has awarded Virtuosi the prestigious Accredited Provider accreditation.
  • IACET Accredited Providers are the only organizations approved to offer IACET Continuing Education Units (CEUs).
  • "We are pleased to recognize and celebrate the achievement of Virtuosi powered by Quality Executive Partners as an Accredited Provider," stated Randy Bowman, President & CEO of IACET.
  • Virtuosi is now linked to the IACET website and is recognized as offering the highest quality continuing education and training programs.

Fiscal Year 2023: Exyte experiences strong growth in Europe and the USA

Retrieved on: 
Tuesday, April 9, 2024
CHIPS, Obesity, Biotechnology, Growth, Cell, Diabetes, Equivalence relation, Artificial intelligence, OSM, Acquisition, Science, Messenger, Investment, Semiconductor, European Chips Act, JGC Holdings Corporation, Inflation, Data, Engineering, EPC, Video game

STUTTGART, Germany, April 9, 2024 /PRNewswire/ -- Exyte GmbH (Exyte), a global leader in the design, engineering, and delivery of high-tech facilities, showed strong growth trajectory in Europe and the USA in its fiscal year 2023.

Key Points: 
  • STUTTGART, Germany, April 9, 2024 /PRNewswire/ -- Exyte GmbH (Exyte), a global leader in the design, engineering, and delivery of high-tech facilities, showed strong growth trajectory in Europe and the USA in its fiscal year 2023.
  • We benefit in Europe and the USA from extensive investments in high-tech facilities," says Exyte CEO Dr. Wolfgang Büchele.
  • The share of Asia is declining, while order intake and sales are increasing significantly in Europe and the USA.
  • In both Europe and the USA, we are expanding our organization to execute our clients' planned mega-projects," says Exyte board member Mark Garvey.